Calcium Bone Turnover Randomized Trial: What the Evidence Says

Quick Answer

Calcium Bone Turnover Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These abnormalities are particularly prevalent in patients undergoing hemodialysis and are associated with clinically important skeletal complications, including renal osteodystrophy, and fractures. [Peng Yu-Sen (2026); evidence level 2]
• High serum phosphate levels have been independently associated with an increased risk of bone fragility fractures in hemodialysis patients, a finding supported by large-scale studies such as the DOPPS/COSMOS project. [Peng Yu-Sen (2026); evidence level 2]
• Accordingly, contemporary guidelines no longer recommend IN-CAL as first-line treatment for chronic osteoporosis, and concerns regarding a potential malignancy signal further limited long-term use. [Ahmad Areeb (2026); evidence level 3]
• A landmark review by Plosker and McTavish summarized the pharmacologic and clinical evidence for IN-CAL through the mid-1990s. [Ahmad Areeb (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For calcium bone turnover randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Peng Yu-Sen (2026). Short-term effects of therapeutic diet on bone turnover markers in hemodialysis patients: an exploratory analysis of a randomized crossover trial. DOI: 10.1038/s41598-026-39820-w. PMCID: PMC13002912. PMID: 41699028. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13002912/
• Ahmad Areeb (2026). Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management. DOI: 10.2106/JBJS.RVW.26.00021. PMCID: PMC13048325. PMID: 41945663. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-Non Commercial-No Derivatives License.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13048325/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.